Strategic expansions Aurigene is expanding with new facilities in Hyderabad and Genome Valley, Alabama, enabling end-to-end discovery through large-scale commercial manufacturing and biologics capabilities. This presents sales opportunities to clients seeking integrated CDMO services across multiple regions and scales.

Integrated offerings The company provides integrated API and formulations development, from starting materials to finished dosage forms, plus traditional discovery and development services. This breadth allows cross-sell to clients needing seamless supply chains and consolidated CRO-CDMO partnerships.

CRISPR and biotech Recent collaboration with ERS Genomics for CRISPR/Cas9 patent access and partnerships with biotech-focused firms indicate a tilt toward cutting-edge gene-editing and advanced technologies, opening opportunities to pitch innovative programs and co-development deals.

Facility scale and capability Significant investments in a $40M Hyderabad biologics facility and expanded campuses enable support for complex biologics, process development, and clinical-to-commercial manufacturing, appealing to sponsors with biologics or large-molecule programs.

Growth and hiring momentum Headcount growth plus capacity expansions imply a robust delivery engine and potential for larger program portfolios. This supports conversations with mid- to large-size sponsors seeking reliable scale, capacity, and reduced time-to-market.